Know the Routine<br />By Rev Shark<br />RealMoney.com Contributor<br />9/29/2009 8:26 AM EDT <br /><br />Most of life is routine -- dull and grubby -- but routine is the momentum that keeps a man going. If you wait for inspiration, you'll be standing on the corner after the parade is a mile down the street. <br />-- Ben Nicholas<br /><br />The action in the market is becoming quite routine. Once again after a few days of weakness it looked like we might actually suffer some technical damage, but we came roaring back and caught anyone who was cautious or defensive by surprise. There was good reason to look for the market to struggle a bit more, but we didn't hesitate for long before the dip-buyers jumped in and drove us up with some very aggressive buying. Volume was a bit light due to the Yom Kippur holiday, but all that did was cause more frustration for bulls who were trying to justify jumping back in despite technical patterns that were not very inviting. <br /><br />So now what? The pattern of the market has been very predictable over the last few months. Once we bounce out of a pullback, we just keep going. In both August and September, the Nasdaq made a new high four days after breaking down. Once we turned back up, there was no hesitation and the buying stayed steady and strong. <br /><br />Do we have any reason to expect the market not to continue this routine pattern of immediate recoveries? Negative fundamentals don't have any impact on this market, and the most dominant theme seems to be that folks are underinvested and trying to add some long exposure. <br /><br />Frankly, this pattern of buying every dip and watching the mad scramble to add long exposure is getting rather tiresome. It doesn't make for the easiest trading when technical patterns are pretty much rendered irrelevant. However, we'd be fools not to recognize the pattern and embrace it. You can get in trouble by fighting the persistent dip-buying just because you have some negative fundamental arguments to make. <br /><br />The biggest challenge facing many, including me, is trying to keep cash at work. Typically I will be a seller on a low-volume day like yesterday, which leaves me in a difficult position if the market continues to run straight back up from here. What works best from a trading standpoint is some ups and downs, and in this market the downs have been so limited that they hardly give time to buy. <br /><br />There is going to be a lot of talk about end-of-the-quarter window dressing. I think window dressing does occur, but it is not a universal phenomenon. Some key stocks benefit from it, many are unaffected and some stocks are sold as a result of it. It may have a net positive impact on the indices, but it's not as reckless and as widespread as many in the market like to think. For the most part, it is finished a day or two before the end of the quarter anyway. Yesterday may have been the big markup day and now things may be more muted. <br /><br />So we are left with the bulls back in control even though the low-volume bounce yesterday was a little technically questionable. The market seems to be looking for us to build on that move with some end-of-the-quarter games, and I would not fight that scenario at this point. <br /><br />Early indications are for some slightly weak action as overseas markets are mixed and the dollar strengthens a little. The dollar has been one of the main drivers lately, so we will have to watch it closely. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: ASTC +75.0% (also announces exploring strategic financial and business alternatives to enhance shareholder value), SSTI +12.0% (light volume), WAG +9.0%, CPSL +6.4%, GCI +3.4% (light volume)... Other news: CIT +16.2% (Creditors eye CIT, IndyMac merger - NY Post), BSDM +15.9% (sells Hyperthermia System to University of California, San Francisco Medical Center), DVAX +11.1% (initiates phase 3 registration trial in chronic kidney disease patients for Heplisavtm hepatitis B vaccine), AEZS +11.1% and KERX +2.1% (KRX-0401 Continues to demonstrate impressive efficacy, safety and tolerability in metastatic renal cell carcinoma patients who progressed after failing treatment with both a VEGF receptor inhibitor and an mTOR inhibitor), MRNA +8.2% (announces patent allowance covering an siRNA with therapeutic potential for oncology and other indications), NVAX +6.6% (still checking), CVS +2.9% (up in sympathy with WAG), AZN +1.4% (AstraZeneca could face bid after 4 bln pounds Solvay takeover - Daily Mail), RBS +1.3% (Royal Bank of Scotland CEO says EU to block sub bond payment, SME loans - DJ)... Analyst comments: RRI +6.1% (upgraded to Conviction Buy from Neutral at Goldman -DJ), RL +2.9% (upgraded to Buy from Neutral at Goldman-DJ), CRXL +2.7% (upgraded to Hold at ING), HBAN +2.4% (upgraded to Outperform at FBR Capital), BRCM +2.4% (upgraded to Overweight at Barclays), JEF +1.0% (upgraded to Mkt Perform at JMP), ETN +1.0% (upgraded to Equal Weight at Barclays). <br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: RCON -17.9%, SIMG -8.3%, SI -2.5% ... Select oil/gas names showing weakness: RDS.B -1.5%, TOT -1.4%, RDS.A -1.1%, REP -1.1%, E -1.0%... Other news: SQNM -41.8% (announces completion of independent investigation; failed to put in place adequate protocols and controls for the conduct of studies in the Trisomy 21 program), RPRX -11.7% (received further clarification from the FDA on the Full Clinical Hold status of Proellex), FR -7.8% (filed for a 12.5 mln share common stock offering pursuant to an existing shelf registration statement), MBI -7.1% (MBIA Inc and MBIA Insurance downgraded at S&P), NLY -4.2% (trading ex dividend), CS -2.4% (still checking), IRET -2.3% (announces public offering of 8,000,000 common shares of beneficial interest)... Analyst comments: PLD -3.1% (downgraded to Perform at Oppenheimer), WNR -2.5% (downgraded to Hold from Buy at Soleil).